Palisade Capital Management’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.72M Buy
23,396
+310
+1% +$72.2K 0.19% 140
2025
Q4
$4.78M Sell
23,086
-484
-2% -$95.7K 0.14% 161
2025
Q3
$4.37M Sell
23,570
-98
-0.4% -$16.8K 0.12% 175
2025
Q2
$3.62M Sell
23,668
-130
-0.5% -$20K 0.1% 187
2025
Q1
$3.95M Sell
23,798
-1,887
-7% -$295K 0.11% 180
2024
Q4
$3.71M Sell
25,685
-8,393
-25% -$1.3M 0.1% 185
2024
Q3
$5.52M Sell
34,078
-22,165
-39% -$3.53M 0.15% 155
2024
Q2
$8.22M Sell
56,243
-22,635
-29% -$3.37M 0.22% 122
2024
Q1
$12.5M Sell
78,878
-11,094
-12% -$1.77M 0.33% 100
2023
Q4
$14.1M Buy
89,972
+522
+0.6% +$80K 0.37% 92
2023
Q3
$13.9M Sell
89,450
-2,130
-2% -$351K 0.39% 88
2023
Q2
$15.2M Sell
91,580
-13
-0% -$2.1K 0.4% 87
2023
Q1
$14.2M Sell
91,593
-593
-0.6% -$95.8K 0.38% 88
2022
Q4
$16.3M Buy
92,186
+179
+0.2% +$30.9K 0.44% 75
2022
Q3
$15M Sell
92,007
-1,111
-1% -$188K 0.43% 79
2022
Q2
$16.5M Sell
93,118
-23
-0% -$4.1K 0.45% 76
2022
Q1
$16.5M Buy
93,141
+250
+0.3% +$42.5K 0.38% 92
2021
Q4
$15.9M Buy
92,891
+476
+0.5% +$77.9K 0.32% 100
2021
Q3
$14.9M Sell
92,415
-584
-0.6% -$99.6K 0.33% 100
2021
Q2
$15.3M Sell
92,999
-373
-0.4% -$61.8K 0.35% 101
2021
Q1
$15.3M Buy
93,372
+1,642
+2% +$266K 0.36% 102
2020
Q4
$14.4M Buy
91,730
+272
+0.3% +$40.1K 0.37% 99
2020
Q3
$13.6M Buy
91,458
+6,021
+7% +$891K 0.4% 88
2020
Q2
$12M Buy
85,437
+4,804
+6% +$700K 0.38% 95
2020
Q1
$10.6M Buy
80,633
+4
+0% +$567 0.37% 88
2019
Q4
$11.8M Buy
80,629
+5
+0% +$678 0.33% 104
2019
Q3
$10.4M Sell
80,624
-2,567
-3% -$338K 0.32% 104
2019
Q2
$11.6M Sell
83,191
-442
-0.5% -$61.2K 0.36% 92
2019
Q1
$11.7M Sell
83,633
-1,158
-1% -$155K 0.38% 87
2018
Q4
$10.9M Sell
84,791
-1,955
-2% -$273K 0.4% 79
2018
Q3
$12M Sell
86,746
-4,785
-5% -$636K 0.33% 94
2018
Q2
$11.1M Sell
91,531
-1,273
-1% -$159K 0.32% 96
2018
Q1
$11.9M Buy
92,804
+9
+0% +$1.22K 0.4% 81
2017
Q4
$13M Buy
92,795
+1,542
+2% +$215K 0.44% 66
2017
Q3
$11.9M Buy
91,253
+4,760
+6% +$631K 0.42% 75
2017
Q2
$11.4M Sell
86,493
-10,325
-11% -$1.32M 0.43% 70
2017
Q1
$12.1M Buy
96,818
+7,427
+8% +$887K 0.46% 66
2016
Q4
$10.3M Buy
89,391
+1,202
+1% +$139K 0.39% 83
2016
Q3
$10.4M Sell
88,189
-1,046
-1% -$127K 0.37% 78
2016
Q2
$10.8M Buy
89,235
+850
+1% +$96.6K 0.39% 74
2016
Q1
$9.56M Sell
88,385
-802
-0.9% -$83K 0.31% 102
2015
Q4
$9.16M Buy
89,187
+862
+1% +$86.7K 0.3% 113
2015
Q3
$8.24M Buy
88,325
+866
+1% +$83.8K 0.24% 148
2015
Q2
$8.52M Sell
87,459
-875
-1% -$87.6K 0.22% 174
2015
Q1
$8.89M Sell
88,334
-257
-0.3% -$26.1K 0.22% 166
2014
Q4
$9.26M Sell
88,591
-4,538
-5% -$478K 0.22% 163
2014
Q3
$9.93M Buy
93,129
+1,825
+2% +$189K 0.25% 155
2014
Q2
$9.55M Sell
91,304
-4,820
-5% -$487K 0.23% 178
2014
Q1
$9.44M Buy
96,124
+3,780
+4% +$350K 0.23% 174
2013
Q4
$8.46M Buy
92,344
+10,661
+13% +$983K 0.22% 173
2013
Q3
$7.08M Sell
81,683
-3,448
-4% -$309K 0.19% 197
2013
Q2
$7.31M Buy
+85,131
New +$7.22M 0.21% 187

Other funds holding JNJ

Palisade Capital Management's JNJ Position: Q1 2026 in Review

Palisade Capital Management increased its Johnson & Johnson (JNJ) stake by 1.3% in Q1 2026, buying an estimated $72.2K and bringing the position to 23,396 shares worth $5.72M. The position accounts for 0.19% of the portfolio, ranked #140.

Palisade Capital Management first reported a position in JNJ in Q2 2013 and has held it in 52 quarters since. The position peaked at $16.5M in Q2 2022. 4,617 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Palisade Capital Management held 23,396 shares of Johnson & Johnson worth $5.72M as of Q1 2026.
  • Palisade Capital Management bought 310 Johnson & Johnson shares in Q1 2026, an estimated $72.2K.
  • Johnson & Johnson made up 0.19% of Palisade Capital Management's portfolio in Q1 2026, its #140 holding.
  • Palisade Capital Management first reported a position in Johnson & Johnson in Q2 2013 and has held it in 52 quarters since.
  • Palisade Capital Management's Johnson & Johnson position peaked at $16.5M in Q2 2022.
  • 4,617 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Palisade Capital Management's 13F filing for Q1 2026, filed 15 May 2026.